These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38145408)

  • 1. RAS Family Gene Mutations, Clinicopathological Features, and Spread Patterns of Inverted Urothelial Papilloma of the Bladder.
    Kitahama K; Shigematsu Y; Amori G; Sugawara E; Yonese J; Shibahara J; Takeuchi K; Inamura K
    Am J Surg Pathol; 2024 Apr; 48(4):458-464. PubMed ID: 38145408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder.
    Isharwal S; Hu W; Sarungbam J; Chen YB; Gopalan A; Fine SW; Tickoo SK; Sirintrapun SJ; Jadallah S; Loo FL; Pietzak EJ; Cha EK; Bochner BH; Berger MF; Iyer G; Solit DB; Reuter VE; Al-Ahmadie H
    J Pathol; 2019 Jul; 248(3):260-265. PubMed ID: 30838648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HRAS mutations are frequent in inverted urothelial neoplasms.
    McDaniel AS; Zhai Y; Cho KR; Dhanasekaran SM; Montgomery JS; Palapattu G; Siddiqui J; Morgan T; Alva A; Weizer A; Lee CT; Chinnaiyan AM; Quist MJ; Grasso CS; Tomlins SA; Mehra R
    Hum Pathol; 2014 Sep; 45(9):1957-65. PubMed ID: 25097040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential.
    Wang CC; Huang CY; Jhuang YL; Chen CC; Jeng YM
    Histopathology; 2018 Apr; 72(5):795-803. PubMed ID: 29193225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Urothelial hyperplastic lesion with endophytic growth pattern: a clinicopathologic study].
    Xiao L; Wang CF; Zhu XZ; Yin YL; Chen Y; Lu C; Yu B
    Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):319-23. PubMed ID: 21756826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change.
    Cheng L; Davidson DD; Wang M; Lopez-Beltran A; Montironi R; Wang L; Tan PH; MacLennan GT; Williamson SR; Zhang S
    Histopathology; 2016 Jul; 69(1):107-13. PubMed ID: 26679899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Significance of TERT promoter mutation in differential diagnosis of non-invasive inverted urothelial lesions of bladder].
    Zhang YH; Xie JJ; Wang JG; Wang Y; Zhan XH; Gao J; He HY
    Zhonghua Bing Li Xue Za Zhi; 2023 Dec; 52(12):1216-1222. PubMed ID: 38058037
    [No Abstract]   [Full Text] [Related]  

  • 9. H-RAS mutation is a key molecular feature of pediatric urothelial bladder cancer. A detailed report of three cases.
    Castillo-Martin M; Collazo Lorduy A; Gladoun N; Hyun G; Cordon-Cardo C
    J Pediatr Urol; 2016 Apr; 12(2):91.e1-7. PubMed ID: 26522772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urothelial lesions with inverted growth patterns: histogenesis, molecular genetic findings, differential diagnosis and clinical management.
    Hodges KB; Lopez-Beltran A; Maclennan GT; Montironi R; Cheng L
    BJU Int; 2011 Feb; 107(4):532-7. PubMed ID: 21091975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inverted papilloma of the bladder: a review and an analysis of the recent literature of 365 patients.
    Picozzi S; Casellato S; Bozzini G; Ratti D; Macchi A; Rubino B; Pace G; Carmignani L
    Urol Oncol; 2013 Nov; 31(8):1584-90. PubMed ID: 22520573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inverted urothelial papilloma of the upper urinary tract: description of two cases with systematic literature review.
    Santi R; Galli IC; Canzonieri V; Lopez JI; Nesi G
    Diagn Pathol; 2020 Apr; 15(1):40. PubMed ID: 32321559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance of the bladder cancer precursor urothelial hyperplasia requires FOXA1 and persistent expression of oncogenic HRAS.
    Yee CH; Zheng Z; Shuman L; Yamashita H; Warrick JI; Wu XR; Raman JD; DeGraff DJ
    Sci Rep; 2019 Jan; 9(1):270. PubMed ID: 30670749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Next-Generation Sequencing of Flat Urothelial Lesions Reveals Putative Pathobiological Pathways, Potential Biomarkers, and Rational Therapeutic Targets.
    Musangile FY; Matsuzaki I; Iwamoto R; Sagan K; Nishikawa M; Mikasa Y; Takahashi Y; Kojima F; Hara I; Murata SI
    Mod Pathol; 2023 May; 36(5):100120. PubMed ID: 36812689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.
    Jebar AH; Hurst CD; Tomlinson DC; Johnston C; Taylor CF; Knowles MA
    Oncogene; 2005 Aug; 24(33):5218-25. PubMed ID: 15897885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct mutational landscape of inverted urothelial papilloma.
    Akgul M; MacLennan GT; Cheng L
    J Pathol; 2019 Sep; 249(1):3-5. PubMed ID: 31119740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer.
    Ouerhani S; Elgaaied AB
    Cancer Biomark; 2011-2012; 10(6):259-66. PubMed ID: 22820081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive high-grade urothelial carcinoma of the bladder, renal pelvis, ureter, and prostatic urethra arising in a background of urothelial carcinoma with an inverted growth pattern: a contemporary clinicopathological analysis of 91 cases.
    Gutierrez CM; Alemozaffar M; Osunkoya AO
    Hum Pathol; 2019 Oct; 92():18-24. PubMed ID: 31351154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic HRAS Activates Epithelial-to-Mesenchymal Transition and Confers Stemness to p53-Deficient Urothelial Cells to Drive Muscle Invasion of Basal Subtype Carcinomas.
    He F; Melamed J; Tang MS; Huang C; Wu XR
    Cancer Res; 2015 May; 75(10):2017-28. PubMed ID: 25795707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glandular-type inverted papilloma of urinary bladder - Report of a unique case with immunohistochemistry.
    Sundaram A; Gupta K; Singla S; Singh SK
    Indian J Pathol Microbiol; 2020; 63(1):96-97. PubMed ID: 32031131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.